PanGen Biotech Inc (222110) — Cash Flow-to-Debt Ratio
PanGen Biotech Inc (222110) has a Cash Flow-to-Debt Ratio of -1.34x as of September 2025, meaning its operating cash flow of ₩-3.66 Billion could theoretically repay -1% of its total liabilities (₩2.74 Billion) in one year. Explore PanGen Biotech Inc (222110) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PanGen Biotech Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for PanGen Biotech Inc across 11 annual periods. Also explore balance sheet size of PanGen Biotech Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for PanGen Biotech Inc (2014–2024)
Year-by-year debt coverage analysis for PanGen Biotech Inc. For market capitalisation and broader financial context, see PanGen Biotech Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.53x | ₩2.99 Billion | ₩5.64 Billion | ▲ +225.6% |
| 2023 | -0.42x | ₩-3.45 Billion | ₩8.18 Billion | ▲ +58.4% |
| 2022 | -1.01x | ₩-3.50 Billion | ₩3.45 Billion | ▼ -576.6% |
| 2021 | -0.15x | ₩-3.32 Billion | ₩22.18 Billion | ▲ +29.2% |
| 2020 | -0.21x | ₩-4.68 Billion | ₩22.10 Billion | ▼ -19.5% |
| 2019 | -0.18x | ₩-3.66 Billion | ₩20.66 Billion | ▲ +41.0% |
| 2018 | -0.30x | ₩-5.61 Billion | ₩18.67 Billion | ▼ -95.7% |
| 2017 | -0.15x | ₩-657.84 Million | ₩4.28 Billion | ▲ +92.6% |
| 2016 | -2.08x | ₩-4.35 Billion | ₩2.09 Billion | ▼ -1107.5% |
| 2015 | -0.17x | ₩-1.61 Billion | ₩9.34 Billion | ▲ +20.6% |
| 2014 | -0.22x | ₩-1.34 Billion | ₩6.18 Billion | — |